The role of thalidomide in dermatology

被引:6
|
作者
Hussain, K. [1 ]
Patel, P. [1 ]
Roberts, N. [1 ]
机构
[1] Chelsea & Westminster Hosp NHS Fdn Trust, Dept Dermatol, London, England
关键词
NECROBIOTIC XANTHOGRANULOMA; THERAPY; LENALIDOMIDE; NEUROPATHY; PATIENT; LESIONS;
D O I
10.1111/ced.15019
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Thalidomide is a medication that has been in existence for over half a century, and has proven to be useful and effective in severe dermatological conditions. For dermatologists, the ability of thalidomide to reduce the levels of the cytokine tumour necrosis factor-alpha, along with its immunomodulatory and anti-angiogenic properties, is of great significance, with the added advantage of being an oral medication. Its use is of course strictly monitored, owing to its potential adverse effects (AEs), particularly teratogenicity, with precautions taken to ensure its safe and correct use by both prescriber and patient. In this review, we look at the background and mechanism of action of thalidomide, provide an overview of conditions it can be used for with case examples, explain the potential AEs and monitoring requirements, and discuss future developments.
引用
收藏
页码:667 / 674
页数:8
相关论文
共 50 条
  • [21] Activity of Thalidomide and Lenalidomide in Mantle Cell Lymphoma
    Richardson, S. J.
    Eve, H. E.
    Copplestone, J. A.
    Dyer, M. J.
    Rule, S. A. J.
    ACTA HAEMATOLOGICA, 2010, 123 (01) : 21 - 29
  • [22] Thalidomide treatment in a myelofibrosis patient with leukemia transformation
    Huang, Wei-Han
    Li, Ming-Shing
    Chu, Sung-Chao
    Wang, Tso-Fu
    Kao, Ruey-Ho
    Wu, Yi-Feng
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (02) : 188 - 192
  • [23] Thalidomide and its analogues in the treatment of Multiple Myeloma
    Tahir Latif
    Nabeel Chauhan
    Rashid Khan
    Andrea Moran
    Saad Z Usmani
    Experimental Hematology & Oncology, 1 (1)
  • [24] Thalidomide and its analogues in the treatment of Multiple Myeloma
    Latif, Tahir
    Chauhan, Nabeel
    Khan, Rashid
    Moran, Andrea
    Usmani, Saad Z.
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2012, 1
  • [25] Type 1 Cryoglobulinemia Response to Thalidomide and Lenalidomide
    Calabrese, Cassandra
    Faiman, Beth
    Martin, David
    Reu, Frederic
    Calabrese, Leonard H.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (03) : 145 - 147
  • [26] Thalidomide in Transfusion Dependent Thalassemia: Hope or Hype
    Kalra, Manas
    Khanna, Virender K.
    Trehan, Amita
    Mahajan, Amita
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (06) : 485 - 485
  • [27] The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review
    Alhazmi, Alya M.
    Basendwh, Mohammad A.
    Aman, Abdullah Ayman
    Dajam, Mazen
    Aljuhani, Turki S.
    DERMATOLOGY AND THERAPY, 2023, 13 (01) : 29 - 49
  • [28] Thalidomide and neurotrophism
    Soper, Judith R.
    Bonar, S. Fiona
    O'Sullivan, Dudley J.
    McCredie, Janet
    Willert, Hans-Georg
    SKELETAL RADIOLOGY, 2019, 48 (04) : 517 - 525
  • [29] Thalidomide:: a comeback?
    Wendling, D
    Toussirot, É
    Michel, F
    JOINT BONE SPINE, 2000, 67 (04) : 259 - 261
  • [30] The thalidomide saga
    Melchert, Magda
    List, Alan
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (7-8): : 1489 - 1499